HRP20010484B1 - Substituted benzimidazoles and their preparation and use - Google Patents
Substituted benzimidazoles and their preparation and useInfo
- Publication number
- HRP20010484B1 HRP20010484B1 HR20010484A HRP20010484A HRP20010484B1 HR P20010484 B1 HRP20010484 B1 HR P20010484B1 HR 20010484 A HR20010484 A HR 20010484A HR P20010484 A HRP20010484 A HR P20010484A HR P20010484 B1 HRP20010484 B1 HR P20010484B1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- phenyl
- hydrogen
- ring
- unbranched
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 150000002431 hydrogen Chemical class 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- -1 cyclic amine Chemical class 0.000 abstract 4
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19854933 | 1998-11-27 | ||
| DE1999116460 DE19916460B4 (de) | 1999-04-12 | 1999-04-12 | Substituierte Benzimidazole, deren Herstellung und Anwendung |
| PCT/EP1999/009004 WO2000032579A1 (de) | 1998-11-27 | 1999-11-23 | Substituierte benzimidazole und ihre verwendung als parp inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20010484A2 HRP20010484A2 (en) | 2003-04-30 |
| HRP20010484B1 true HRP20010484B1 (en) | 2010-08-31 |
Family
ID=26050434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010484A HRP20010484B1 (en) | 1998-11-27 | 2001-06-26 | Substituted benzimidazoles and their preparation and use |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | USRE39608E1 (ru) |
| EP (1) | EP1133477B1 (ru) |
| JP (1) | JP3432800B2 (ru) |
| KR (1) | KR100417779B1 (ru) |
| CN (1) | CN1184208C (ru) |
| AR (1) | AR021400A1 (ru) |
| AT (1) | ATE259789T1 (ru) |
| AU (1) | AU764216B2 (ru) |
| BG (1) | BG65047B1 (ru) |
| BR (1) | BR9915701A (ru) |
| CA (1) | CA2352554C (ru) |
| CZ (1) | CZ300148B6 (ru) |
| DE (1) | DE59908600D1 (ru) |
| DK (1) | DK1133477T3 (ru) |
| ES (1) | ES2216625T3 (ru) |
| HK (1) | HK1042084B (ru) |
| HR (1) | HRP20010484B1 (ru) |
| HU (1) | HUP0200749A3 (ru) |
| IL (2) | IL143303A0 (ru) |
| MY (1) | MY128488A (ru) |
| NO (1) | NO20012570L (ru) |
| NZ (1) | NZ511825A (ru) |
| PL (1) | PL196367B1 (ru) |
| PT (1) | PT1133477E (ru) |
| RU (1) | RU2001117757A (ru) |
| SI (1) | SI1133477T1 (ru) |
| SK (1) | SK285529B6 (ru) |
| TR (1) | TR200101498T2 (ru) |
| TW (1) | TWI247741B (ru) |
| UA (1) | UA61158C2 (ru) |
| WO (1) | WO2000032579A1 (ru) |
| ZA (1) | ZA200104118B (ru) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20011546A3 (cs) | 1998-11-03 | 2001-08-15 | Basf Aktiengesellschaft | Derivát substituovaného 2-fenylbenzimidazolu, způsob jeho přípravy a jeho použití |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| PT1309594E (pt) | 2000-08-08 | 2005-04-29 | Sanofi Aventis | Derivados de benzimidazole a sua preparacao e a sua aplicacao em terapeutica |
| FR2812878B1 (fr) * | 2000-08-08 | 2002-10-11 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| FR2816942B1 (fr) * | 2000-11-23 | 2003-05-09 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| FR2816941B1 (fr) * | 2000-11-23 | 2003-01-31 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| WO2002068407A1 (fr) * | 2001-02-28 | 2002-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Compose benzimidazole |
| WO2002072090A1 (en) | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| US20040242635A1 (en) * | 2001-03-30 | 2004-12-02 | Painter Rachel J. | Encapsulated dyes in cosmetic compositions |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| US7786344B2 (en) | 2002-07-26 | 2010-08-31 | Basf Plant Science Gmbh | Selection method |
| WO2004014873A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
| HU0301154D0 (en) * | 2003-04-28 | 2003-07-28 | Hideg Kalman Dr | Pharmaceutical composition |
| CN102925479A (zh) | 2005-03-08 | 2013-02-13 | 巴斯福植物科学有限公司 | 增强表达的内含子序列 |
| JP5066514B2 (ja) * | 2005-03-14 | 2012-11-07 | ハイ ポイント ファーマシューティカルズ，エルエルシー | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| AU2012200399B2 (en) * | 2005-04-11 | 2013-07-11 | Abbvie Ireland Unlimited Company | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors |
| EP1904468A4 (en) * | 2005-06-10 | 2009-04-22 | Bipar Sciences Inc | PARP MODULATORS AND TREATMENT OF CANCER |
| US7825543B2 (en) | 2005-07-12 | 2010-11-02 | Massachusetts Institute Of Technology | Wireless energy transfer |
| EP1902505B1 (en) | 2005-07-12 | 2021-09-01 | Massachusetts Institute of Technology (MIT) | Wireless non-radiative energy transfer |
| CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| WO2007041357A1 (en) | 2005-09-29 | 2007-04-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| EP1779849A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of septic shock |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| RS53082B (en) * | 2006-01-17 | 2014-06-30 | Abbvie Bahamas Ltd. | COMBINED THERAPY WITH PARP INHIBITORS |
| US20080293795A1 (en) * | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20080280867A1 (en) * | 2006-01-17 | 2008-11-13 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20090029966A1 (en) * | 2006-01-17 | 2009-01-29 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20080146638A1 (en) * | 2006-01-17 | 2008-06-19 | Abbott Laboratories | Combination therapy with parp inhibitors |
| JP4611441B2 (ja) * | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
| ATE553104T1 (de) * | 2006-05-02 | 2012-04-15 | Abbott Lab | Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer |
| US20070292883A1 (en) * | 2006-06-12 | 2007-12-20 | Ossovskaya Valeria S | Method of treating diseases with PARP inhibitors |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| AU2008204380B2 (en) | 2007-01-10 | 2013-08-15 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| BRPI0809655B8 (pt) * | 2007-04-13 | 2021-05-25 | Millennium Pharm Inc | uso de um composto e um agente terapêutico,composição farmacêutica,e,kit |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| US8138168B1 (en) * | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| MX2010003771A (es) * | 2007-10-12 | 2010-04-21 | Abbott Lab | Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida. |
| CN103169973A (zh) | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| KR20100102607A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| AU2009203598B2 (en) * | 2008-01-08 | 2013-09-26 | Merck Sharp & Dohme Llc | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide |
| WO2009100159A2 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| EP2247600A4 (en) * | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| US8513433B2 (en) | 2009-07-02 | 2013-08-20 | Angion Biomedica Corp. | Small molecule inhibitors of PARP activity |
| CN102762726A (zh) | 2009-11-27 | 2012-10-31 | 巴斯夫植物科学有限公司 | 嵌合内切核酸酶及其用途 |
| WO2011064750A1 (en) | 2009-11-27 | 2011-06-03 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
| EP2504439B1 (en) | 2009-11-27 | 2016-03-02 | BASF Plant Science Company GmbH | Optimized endonucleases and uses thereof |
| AR080443A1 (es) | 2010-03-04 | 2012-04-11 | Bayer Cropscience Ag | 2-amidobencimidazoles sustituidos con fluruoalquilo |
| CA2833914A1 (en) * | 2011-05-10 | 2012-11-15 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
| JP5902299B2 (ja) * | 2011-07-26 | 2016-04-13 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体 |
| EP2561759A1 (en) | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102617502A (zh) * | 2012-03-19 | 2012-08-01 | 江苏先声药物研究有限公司 | 一类苯并噁唑衍生物及其医药应用 |
| AU2013311826A1 (en) * | 2012-09-05 | 2015-03-26 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
| GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
| CN104230897B (zh) * | 2013-06-17 | 2016-07-06 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
| CN104230898B (zh) * | 2013-06-17 | 2016-06-29 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
| CN103483322A (zh) * | 2013-08-21 | 2014-01-01 | 中国药科大学 | 5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途 |
| CN103396405A (zh) * | 2013-08-21 | 2013-11-20 | 中国药科大学 | 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物 |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| ES2973850T3 (es) * | 2016-09-20 | 2024-06-24 | Centre Leon Berard | Derivados del benzoimidazol como agentes anticancerígenos |
| CN110300600A (zh) | 2016-11-02 | 2019-10-01 | 伊缪诺金公司 | 利用抗体-药物缀合物和parp抑制剂的组合治疗 |
| CN109232540A (zh) * | 2018-06-15 | 2019-01-18 | 深圳市坤健创新药物研究院 | 一种取代苯并咪唑衍生物及应用 |
| CN108997320A (zh) * | 2018-08-30 | 2018-12-14 | 深圳市坤健创新药物研究院 | 一种含氟取代苯并咪唑衍生物及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004771A1 (en) * | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
| WO1998033802A1 (en) * | 1997-02-01 | 1998-08-06 | Newcastle University Ventures Limited | Quinazolinone compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1354554U (ru) | ||||
| US4093726A (en) | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| US6303627B1 (en) | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
-
1999
- 1999-11-23 DK DK99964497T patent/DK1133477T3/da active
- 1999-11-23 SI SI9930543T patent/SI1133477T1/xx unknown
- 1999-11-23 UA UA2001064494A patent/UA61158C2/ru unknown
- 1999-11-23 CZ CZ20011855A patent/CZ300148B6/cs not_active IP Right Cessation
- 1999-11-23 BR BR9915701-2A patent/BR9915701A/pt not_active IP Right Cessation
- 1999-11-23 TR TR2001/01498T patent/TR200101498T2/xx unknown
- 1999-11-23 AT AT99964497T patent/ATE259789T1/de active
- 1999-11-23 US US10/935,683 patent/USRE39608E1/en not_active Expired - Lifetime
- 1999-11-23 KR KR10-2001-7006611A patent/KR100417779B1/ko not_active IP Right Cessation
- 1999-11-23 CA CA002352554A patent/CA2352554C/en not_active Expired - Fee Related
- 1999-11-23 WO PCT/EP1999/009004 patent/WO2000032579A1/de active IP Right Grant
- 1999-11-23 IL IL14330399A patent/IL143303A0/xx active IP Right Grant
- 1999-11-23 DE DE59908600T patent/DE59908600D1/de not_active Expired - Lifetime
- 1999-11-23 SK SK714-2001A patent/SK285529B6/sk not_active IP Right Cessation
- 1999-11-23 PL PL347884A patent/PL196367B1/pl unknown
- 1999-11-23 EP EP99964497A patent/EP1133477B1/de not_active Expired - Lifetime
- 1999-11-23 US US09/856,686 patent/US6448271B1/en not_active Ceased
- 1999-11-23 NZ NZ511825A patent/NZ511825A/en not_active IP Right Cessation
- 1999-11-23 PT PT99964497T patent/PT1133477E/pt unknown
- 1999-11-23 AU AU30343/00A patent/AU764216B2/en not_active Ceased
- 1999-11-23 ES ES99964497T patent/ES2216625T3/es not_active Expired - Lifetime
- 1999-11-23 CN CNB998151130A patent/CN1184208C/zh not_active Expired - Fee Related
- 1999-11-23 RU RU2001117757/04A patent/RU2001117757A/ru unknown
- 1999-11-23 HU HU0200749A patent/HUP0200749A3/hu unknown
- 1999-11-23 JP JP2000585221A patent/JP3432800B2/ja not_active Expired - Fee Related
- 1999-11-25 AR ARP990106011A patent/AR021400A1/es unknown
- 1999-11-26 TW TW088120715A patent/TWI247741B/zh not_active IP Right Cessation
- 1999-11-27 MY MYPI99005192A patent/MY128488A/en unknown
-
2001
- 2001-05-21 ZA ZA200104118A patent/ZA200104118B/xx unknown
- 2001-05-22 IL IL143303A patent/IL143303A/en not_active IP Right Cessation
- 2001-05-25 NO NO20012570A patent/NO20012570L/no not_active Application Discontinuation
- 2001-06-13 BG BG105596A patent/BG65047B1/bg unknown
- 2001-06-26 HR HR20010484A patent/HRP20010484B1/xx not_active IP Right Cessation
-
2002
- 2002-05-04 HK HK02103400.6A patent/HK1042084B/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004771A1 (en) * | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
| WO1998033802A1 (en) * | 1997-02-01 | 1998-08-06 | Newcastle University Ventures Limited | Quinazolinone compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20010484B1 (en) | Substituted benzimidazoles and their preparation and use | |
| HRP20020617B1 (en) | Substituted oxazolidinones and ther use in the field of blood coagulation | |
| RS51044B (sr) | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni | |
| MY100040A (en) | Substituted azabicyclo compounds. | |
| HRP20110498T1 (hr) | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti | |
| CA2405521A1 (en) | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties | |
| RS50955B (sr) | Derivati ksantina, njihovo dobijanje i njihova primena kao lekova | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| HUP0001607A2 (hu) | Tienopirimidinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás ezek előállítására, valamint e vegyületek alkalmazása | |
| HRP20080023T3 (en) | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
| CA2474192A1 (en) | Nicotinamide derivates useful as p38 inhibitors | |
| DE60107435D1 (de) | 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission | |
| RS50680B (sr) | Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja | |
| KR960029335A (ko) | 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온 | |
| RS50677B (sr) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju bipolarnog poremaćaja | |
| RS50772B (sr) | Pentafluorsulfanil-benzoilgvandini, postupak za njihovu proizvodnju, njihova primena u svojstvu leka ili dijagnostičkog sredstva kao i lek koji sadrži ova jedinjenja | |
| AR048326A1 (es) | Derivados de prolinilo | |
| RS50505B (sr) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja | |
| RS51056B (sr) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja | |
| HUP0301183A2 (hu) | Eljárás pirazolo-pirimidinonok előállítására | |
| HUP0000233A2 (hu) | Pirazolinon-származékok alkalmazása potenciazavarok kezelésére szolgáló gyógyszerkészítmények előállítására | |
| PT934278E (pt) | Bis(acridinocarboxamida) e bis(fenazinocarboxamida) como agentes antitumorais | |
| HUP0001010A2 (hu) | Benzimidazol-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| ES449765A1 (es) | Procedimiento para la preparacion de nuevas homoftalimidas. | |
| HUP0301884A2 (hu) | Szubsztituált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok gyógyszerként történż alkalmazása |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: ABBOTT GMBH, DE Owner name: ABBOTT GMBH & CO. KG, DE Owner name: ABBOTT DEUTSCHLAND HOLDING GMBH, DE |
|
| PPPP | Transfer of rights |
Owner name: ABBVIE BAHAMAS LTD., BS Owner name: ABBVIE DEUTSCHLAND GMBH & CO. KG, DE Owner name: ABBVIE IRELAND UNLIMITED COMPANY, BM Owner name: GOLIATH HUNDERTZEHNTE VERMOEGENSVERWALTUNGSGESELLS |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20171123 Year of fee payment: 19 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20181123 |